This antibody SI-B001 is a significant step forward in hematologic management of refractory multiple myeloma. The innovative antibody directly binds to BCMA on myeloma malignancies, triggering BCMA-dependent cellular cytotoxicity and promoting tumor-killing body's responses. Preliminary investigatio